Pivotal molecules of MHC I pathway in human primary hepatocellular carcinoma

World J Gastroenterol. 2005 Jun 7;11(21):3297-9. doi: 10.3748/wjg.v11.i21.3297.

Abstract

Aim: To investigate the expression of several important molecules involved in major histocompatibility complex (MHC) class I presentation pathway in primary hepatocellular carcinoma (HCC), and to determine whether cytotoxic T lymphocyte (CTL) vaccine therapy was suitable for HCC.

Methods: Labeled streptavidin biotin (LSAB) method of immunohistochemistry was used to study 33 HCC tissue specimens.

Results: Most HCC tissues and adjacent histological normal hepatocytes expressed HLA-I antigens,TAP, and B7, expression of B7 was especially strong, and there was no significant difference between them (P>0.05).

Conclusion: The MHC class I presentation pathway in primary hepatocellular carcinoma may not be abnormal or dysfunctional, and CTL could kill these tumor cells. Thus, it is suitable and practicable to design and construct CTL vaccine against HCC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cancer Vaccines*
  • Carcinoma, Hepatocellular / immunology*
  • Carcinoma, Hepatocellular / metabolism
  • Carcinoma, Hepatocellular / therapy
  • Histocompatibility Antigens Class I / immunology*
  • Histocompatibility Antigens Class I / metabolism
  • Humans
  • Liver Neoplasms / immunology*
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / therapy
  • T-Lymphocytes, Cytotoxic / immunology

Substances

  • Cancer Vaccines
  • Histocompatibility Antigens Class I